PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28726161-0 2018 Celastrol specifically inhibits the activation of NLRP3 inflammasome. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 50-55 33130474-0 2021 Celastrol ameliorates Propionibacterium acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 142-147 28978034-0 2017 Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 57-62 28978034-3 2017 Here, we show that celastrol abolishes the NLRP3 inflammasome activation, inhibits subsequent caspase-1 activation and IL-1beta secretion both in vitro and in vivo. celastrol 19-28 NLR family pyrin domain containing 3 Homo sapiens 43-48 28978034-4 2017 Notably, interruption of ASC oligomerization and autophagy activation are involved in NLRP3 inflammasome inactivation by celastrol. celastrol 121-130 NLR family pyrin domain containing 3 Homo sapiens 86-91 28978034-5 2017 Importantly, in vivo results indicate that celastrol attenuates NLRP3 inflammasome-dependent inflammation diseases via autophagy-related pathway. celastrol 43-52 NLR family pyrin domain containing 3 Homo sapiens 64-69 28978034-6 2017 Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases. celastrol 24-33 NLR family pyrin domain containing 3 Homo sapiens 53-58 28978034-6 2017 Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases. celastrol 24-33 NLR family pyrin domain containing 3 Homo sapiens 142-147 28978034-6 2017 Our results thus reveal celastrol as an inhibitor of NLRP3 inflammasome, implying the potential for clinical use of celastrol in treatment of NLRP3 inflammasome-driven inflammatory diseases. celastrol 116-125 NLR family pyrin domain containing 3 Homo sapiens 142-147 34600334-5 2021 Whole-genome deep sequencing analysis revealed that Nrf2, NLRP3 and caspase-1 in SNc may be associated with the neuroprotective actions of celastrol in PD. celastrol 139-148 NLR family pyrin domain containing 3 Homo sapiens 58-63 34147915-0 2021 Celastrol inhibits rheumatoid arthritis through the ROS-NF-kappaB-NLRP3 inflammasome axis. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 66-71 33130474-3 2021 PURPOSE: This study aims to investigate whether the inhibition of NLRP3 inflammasome is engaged in the anti-inflammatory activities of celastrol and delineate the underlying mechanism. celastrol 135-144 NLR family pyrin domain containing 3 Homo sapiens 66-71 33130474-9 2021 Celastrol suppressed NLRP3 inflammasome activation and alleviated P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 21-26 33130474-10 2021 Mechanism study revealed that celastrol could interdict K63 deubiquitination of NLRP3, which may concern interaction of celastrol and BRCA1/BRCA2-containing complex subunit 3 (BRCC3), and thereby prohibited the formation of NLRP3, ASC and pro-caspase-1 complex to block the generation of mature IL-1beta. celastrol 30-39 NLR family pyrin domain containing 3 Homo sapiens 80-85 33130474-10 2021 Mechanism study revealed that celastrol could interdict K63 deubiquitination of NLRP3, which may concern interaction of celastrol and BRCA1/BRCA2-containing complex subunit 3 (BRCC3), and thereby prohibited the formation of NLRP3, ASC and pro-caspase-1 complex to block the generation of mature IL-1beta. celastrol 30-39 NLR family pyrin domain containing 3 Homo sapiens 224-229 33130474-11 2021 CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases. celastrol 12-21 NLR family pyrin domain containing 3 Homo sapiens 33-38 33130474-11 2021 CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases. celastrol 12-21 NLR family pyrin domain containing 3 Homo sapiens 171-176 33130474-11 2021 CONCLUSION: Celastrol suppresses NLRP3 inflammasome activation in P. acnes/LPS-induced liver damage and MSU-induced gouty arthritis via inhibiting K63 deubiquitination of NLRP3, which presents a novel insight into inhibition of celastrol on NLRP3 inflammasome and provides more evidences for its application in the therapy of inflammation-related diseases. celastrol 12-21 NLR family pyrin domain containing 3 Homo sapiens 171-176 31285857-0 2019 Celastrol attenuates ox-LDL-induced mesangial cell proliferation via suppressing NLRP3 inflammasome activation. celastrol 0-9 NLR family pyrin domain containing 3 Homo sapiens 81-86 31285857-8 2019 As expected, celastrol pretreatment strikingly inhibited NLRP3 inflammasome activation and MC proliferation triggered by ox-LDL. celastrol 13-22 NLR family pyrin domain containing 3 Homo sapiens 57-62 31285857-9 2019 In summary, celastrol potently blocked ox-LDL-induced MC proliferation, possibly by inhibiting NLRP3 inflammasome activation. celastrol 12-21 NLR family pyrin domain containing 3 Homo sapiens 95-100